Travere Therapeutics (TVTX) Tops Q4 EPS by 31c

Travere Therapeutics (NASDAQ: TVTX) reported Q4 EPS of ($0.76), $0.31 better than the analyst estimate of ($1.07). Revenue for the quarter came in at $52.3 million versus the consensus estimate of $56.99 million.

For earnings history and earnings-related data on Travere Therapeutics (TVTX) click here.

You May Also Be Interested In

• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
• Credo Technology shares rise on analyst support and conference comments
• HP Inc. projects mid-single-digit PC market decline in 2027